Armata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M [Seeking Alpha]
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape [Yahoo! Finance]
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags [Seeking Alpha]